Cell-based Assay Market Destined to Reach US$ 33.6 Billion (CAGR of 8.3%) During 2023-2028 | IMARC Group

According to the latest report by IMARC Group, titled "Cell-based Assay Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", offers a comprehensive analysis of the industry, which comprises insights on the global cell-based assay market. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global cell-based assay market size reached US$ 20.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.6 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.

The cell-based assay is a laboratory technique used to study the behavior of cells in response to various stimuli, such as drugs, chemicals, or pathogens. It involves growing cells in vitro and exposing them to the stimulus of interest. Researchers then use various techniques, such as microscopy or flow cytometry, to measure the cellular response. The cell-based assay is used in drug discovery, toxicity testing, and basic research. It provides a reliable and reproducible method for evaluating cellular function and is widely used in the biotechnology and pharmaceutical industries.

Request Free Sample Report: https://www.imarcgroup.com/cell-based-assays-market/requestsample

Market Trends:

The global market is majorly driven by the increasing demand for more efficient and effective drug discovery methods. In line with this, the growing focus on personalized medicine and targeted therapies is significantly contributing to the market growth. Furthermore, the rising focus on drug discovery and development is positively influencing the market. Apart from this, the rapid technological advancements and automation in cell-based assays are offering lucrative opportunities for the market.

Moreover, the escalating prevalence of chronic diseases such as cancer and autoimmune disorders is catalyzing the market. Besides, the increasing demand for cell-based assays in toxicity testing and environmental monitoring is propelling the market. Additionally, the rising use of cell-based assays in preclinical drug development and the emergence of 3D cell culture techniques for improved assay performance is anticipated to provide a boost to the market.

By the IMARC Group, Some of the Top Cell-Based Assay Companies Operating in the Market are Given Below:

• Becton Dickinson and Company
• GE Healthcare Biopharma (Danaher Corporation)
• Thermo Fisher Scientific Inc.
• Merck Group
• Perkinelmer Inc.
• Charles River Laboratories Inc.
• Lonza Group Ltd.
• Cell Signaling Technology Inc.
• Promega Corporation
• Cell Biolabs Inc.
• Bio-Rad Laboratories Inc.
• Corning Inc.
• F. Hoffmann-La Roche AG (Roche Holding AG)

Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/cell-based-assays-market

Key Market Segmentation:

Breakup by Product and Services:

• Consumables
o Reagents and Media
o Cells and Cell Lines
o Probes and Labels
• Instruments
o Microplates
o Microplate Readers
o High Throughput Screening
o Liquid Handling Systems
o Services
• Software

Breakup by Technology:

• Automated Handling
• Flow Cytometry
• Label-Free Detection
• High-Throughput Screening
• Others

Breakup by Application:

• Drug Discovery
• Basic Research
• ADME Studies
• Predictive Toxicology
• Others

Breakup by End-User:

• Pharmaceutical and Biotechnology Companies
• Academic and Government Institutions
• Contract Research Organizations
• Others

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the Report:

• Market Performance (2017-2022)
• Market Outlook (2023-2028)
• COVID-19 Impact on the Market
• Porter's Five Forces Analysis
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Explore the Most Recently Released Plant Setup Report:

• Lithium Hypochlorite Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/lithium-hypochlorite-manufacturing-plant-project-report

• Ethyl Sulfate Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/ethyl-sulfate-manufacturing-plant-project-report

• Ethyl Salicylate Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/ethyl-salicylate-manufacturing-plant-project-report

• Glycerin Monostearate Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/glycerin-monostearate-manufacturing-plant-project-report

• Glycerol Triacetate Manufacturing Plant Project Report 2023: https://www.imarcgroup.com/glycerol-triacetate-manufacturing-plant-project-report

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company's expertise.

This release was published on openPR.